Editas Medicine plans to lay off 65% of its staff, around 180 employees, due to financial struggles in the gene-editing field. The company’s stock has fallen 81% this year, and it has faced challenges in developing successful gene-editing programs. In contrast, Eli Lilly’s Mounjaro is gaining popularity over Novo Nordisk’s Wegovy in the U.K. for obesity treatment due to its efficacy. Private patients are increasingly choosing Mounjaro, and it may soon be available through the U.K.’s National Health Service. The government has the capacity to treat about 35,000 patients for obesity but lacks public data on prescription numbers.
Source link
Pharmalittle: We’re reading about Editas layoffs, House Republicans probing CVS, and more
